多基因组学分析揭示了慢性脏疾病与沙科佩尼亚治疗点
Meiqiu Wang1, Lianghui You2, Xu He3
1Department of Pediatrics, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Journal of cachexia, sarcopenia and muscle
|February 6, 2025
概括
这项研究表明,所分泌的蛋白质Spp1在慢性病 (CKD) 中驱动肌肉消耗. 抑制Spp1对治疗CKD患者的缩症有希望.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 肌肉生理学 肌肉生理学
- 分子生物学分子生物学
背景情况:
- 软骨症或肌肉衰竭在慢性病 (CKD) 中很常见,并且与患者的不良结果有关.
- 在CKD中肌肉损失背后的精确机制仍然不完全理解.
- 这项研究探讨了脏分泌的物质如何影响肌肉组织.
研究的目的:
- 研究慢性病 (CKD) 肌肉消耗的分子机制.
- 为了确定影响慢性瘤中萨尔科佩尼亚的关键脏衍生因素.
- 评估Spp1作为CKD相关的萨尔科佩尼亚的潜在治疗标.
主要方法:
- 从CKD和对照小鼠的脏,血清和肌肉组织的多基因组测序 (RNA-seq,TMT).
- 在体外研究中,使用C2C12神经管与Spp1重组蛋白治疗.
- 在体内实验涉及药理抑制Spp1在CKD小鼠模型中的实验.
主要成果:
- 多基因分析确定Spp1是CKD脏,血清和肌肉中共同调节的蛋白质.
- 在体外,Spp1促进了肌管缩,增加了肌肉缩标志物 (Murf-1) 的表达.
- 药理上Spp1抑制在体内改善肌肉质量和改善CKD小鼠的缩.
结论:
- 这项研究建立了一个-肌肉交叉声调节网络,阐明了与CKD相关的肉症的机制.
- 在CKD中,Spp1被确定为肌肉消耗的关键调解者.
- 在患有慢性瘤的患者中,Spp1代表了管理类病的潜在治疗标.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K